• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » In Brief: Antipsychotic Update

In Brief: Antipsychotic Update

January 13, 2020
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

FDA Clears the Path for Magic Mushrooms. Psilocybin, the psychedelic compound in magic mushrooms, was fast-tracked by the FDA for major depression in November 2019. A phase 2 trial is currently underway by the nonprofit Usona Institute with completion expected by 2021. A separate company, Compass Pharmaceuticals, is testing psilocybin in treatment-resistant depression.


What we know about this serotonin-2 agonist is that it brought rapid relief to treatment-resistant depression in a small open-label trial in 2016. Improvement was seen after 2 doses, and the gains were maintained 6 months later without further dosing. Confirmation of these antidepressant effects has been limited to a small randomized, placebo-controlled trial in patients with depression and terminal cancer.


Psilocybin’s antidepressant effects appear linked to the quality of the spiritual experiences induced by the drug. When it works, it enhances gratitude, forgiveness, death transcendence, religious faith, and closeness to nature and humanity. On the other hand, psilocybin can cause frightening alterations of consciousness. The drug is usually administered in the context of a supportive psychotherapy to foster a safe environment and bring out the positive in its transcendent effects. Similar spiritual experiences have been described on ketamine, and we covered those reports in our July 8, 2019 podcast, “The Secret History of Ketamine.”

General Psychiatry
    www.thecarlatreport.com
    Issue Date: January 13, 2020
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Esketamine, TCPR, January 2020
    How to Treat Tardive Dyskinesia
    Getting Uncomfortable with Esketamine
    Antipsychotic Maintenance: How Long is Enough?
    TMS: Deeper is not Better
    In Brief: Antipsychotic Update
    DOWNLOAD NOW
    Featured Book
    • MFB6eCover.jpg

      Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

      Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • canstockphoto22709844.jpg
      General Psychiatry

      Psychopharm Commandment #10: Don’t Fear these Meds

      Surprising health benefits of our riskiest meds: Lithium, quetiapine, and clozapine.

      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.